Related Experiment Video
Updated: Sep 5, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Impact of Myocardial Fibrosis on Cardiovascular Structure, Function and Functional Status in Heart Failure with
Gavin A Lewis1,2, Anna Rosala-Hallas3, Susanna Dodd4
1Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.
Insights
Antifibrotic therapy improved heart failure symptoms, but regression of myocardial fibrosis did not significantly improve left ventricular ejection fraction (LVEF) in patients with heart failure with preserved ejection fraction (HFpEF).
Area of Science:
- Cardiology
- Biomedical Engineering
- Translational Medicine
Background:
- Myocardial fibrosis is linked to poor outcomes in heart failure with preserved ejection fraction (HFpEF).
- The precise mechanisms by which fibrosis impacts cardiovascular function in HFpEF remain incompletely understood.
Purpose of the Study:
- To investigate if regression of myocardial fibrosis mediates improvements in cardiovascular function and functional status after antifibrotic therapy.
- To analyze the causal mediation effects of fibrosis components on left ventricular ejection fraction (LVEF) in HFpEF patients.
Main Methods:
- Mediation analyses were conducted on data from the Pirfenidone in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction (PIROUETTE) trial.
- Cardiovascular magnetic resonance extracellular volume (ECV) was used to measure myocardial fibrosis.
Main Results:
- Regression of myocardial fibrosis correlated with enhanced 6-minute walk test performance and KCCQ clinical summary scores.
- Left ventricular ejection fraction (LVEF) showed a treatment effect, increasing post-therapy.
- No significant causal mediation effects were found for myocardial ECV, extracellular matrix volume, or cellular volume on LVEF.
Conclusions:
- While antifibrotic therapy shows benefits in HFpEF functional status, myocardial fibrosis regression does not appear to be the primary mediator of LVEF improvement.
- Further research is needed to elucidate the mechanisms linking fibrosis to adverse outcomes and therapeutic responses in HFpEF.
Abstract:
Myocardial fibrosis, measured using cardiovascular magnetic resonance extracellular volume (ECV), is associated with adverse outcome in heart failure with preserved ejection fraction, but the mechanisms by which myocardial fibrosis exerts this deleterious effect are unclear. We performed mediation analyses of data from the Pirfenidone in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction (PIROUETTE) trial to determine whether myocardial fibrotic regression causes changes in cardiovascular function and functional status following antifibrotic therapy. Regression of myocardial fibrosis correlated with improvements in 6-min walk test and KCCQ clinical summary score. The only outcome variable that demonstrated a treatment effect was an increase in left ventricular ejection fraction (LVEF). The estimated average causal mediation effects of myocardial ECV, absolute myocardial extracellular matrix volume and absolute myocardial cellular volume on LVEF were 6.1%, 21.5% and 13.7%, respectively, none of which was significant and therefore not mediated by myocardial fibrosis. (PIROUETTE; NCT02932566).
More Related Videos
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
09:37Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Myocarditis I: Introduction
Heart Failure IV: Classification and Diagnostic Evaluation